Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02876510 · ClinicalTrials.gov registry record · Phase 1
ACTolog in Patients With Solid Cancers
A Phase 1 study, sponsored by Immatics US.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT02876510: Completed Phase 1 study, sponsored by Immatics US.
NCT02876510 is a Phase 1 study that has completed, run by Immatics US. The registered enrollment target is 38 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (37% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02876510, a Phase 1 study, has completed, sponsored by Immatics US.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The study purpose is to learn about the safety and tolerability of IMA101 alone (Cohort 1) or in combination with atezolizumab (Cohort 2) in patients with advanced solid cancers that express pre-defined Immatics tumor targets.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL IMA101 product
- BIOLOGICAL Recombinant human interleukin-2
- DIAGNOSTIC_TEST IMADetect
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2017-06-30 |
| Est. Completion | 2021-09-22 |
| Phase | Phase 1 |
What the finished NCT02876510 record still lists
NCT02876510 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (37% lower).
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02876510 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02876510 about?
NCT02876510 is a clinical study titled "ACTolog in Patients With Solid Cancers". The study purpose is to learn about the safety and tolerability of IMA101 alone (Cohort 1) or in combination with atezolizumab (Cohort 2) in patients with advanced solid cancers that express pre-defined Immatics tumor targets.
What is the current status of trial NCT02876510?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2017-06-30. Estimated completion is 2021-09-22.
What interventions are being tested in trial NCT02876510?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), IMA101 product (BIOLOGICAL), Recombinant human interleukin-2 (BIOLOGICAL), IMADetect (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT02876510?
This trial is sponsored by Immatics US, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02876510's enrollment target sits among peer trials
38 1197th of 2000 higher than 797 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI